Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.

IF 17.5 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2026-06-19 DOI:10.1186/s40164-026-00803-2

Chenchen Ma, Siyuan Cui, Jingyi Wang

引用次数: 0

Abstract

Menin inhibition has emerged as a promising therapeutic strategy for acute myeloid leukemia (AML) driven by KMT2A rearrangements or NPM1 mutations. Novel menin inhibitors, including revumenib, bleximenib, ziftomenib, and enzomenib, are currently under clinical evaluation, and selected updated clinical results were presented at the 2025 American Society of Hematology (ASH) Annual Meeting. This brief review summarizes the key findings and discusses the emerging clinical questions regarding combination strategies, treatment sequencing, and molecularly defined use of menin inhibitors.

查看原文本刊更多论文

急性髓系白血病menin抑制剂的临床研究进展：来自2025年ASH年会的最新进展。

Menin抑制已成为由KMT2A重排或NPM1突变驱动的急性髓性白血病（AML）的一种有希望的治疗策略。新型menin抑制剂，包括revumenib、bleximenib、ziftomenib和enzomenib，目前正在进行临床评估，并在2025年美国血液学学会（ASH）年会上公布了一些最新的临床结果。这篇简短的综述总结了主要发现，并讨论了关于联合策略、治疗顺序和menin抑制剂分子定义使用的新出现的临床问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.